MGC Pharmaceuticals Limited
MGCLF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.52 | 0.12 | -0.06 |
| FCF Yield | -68.82% | -29.38% | -20.03% | -18.18% |
| EV / EBITDA | -1.33 | -3.50 | -4.52 | -3.22 |
| Quality | ||||
| ROIC | -257.31% | -114.80% | -51.62% | -230.08% |
| Gross Margin | 37.96% | 33.01% | 24.58% | -14.72% |
| Cash Conversion Ratio | 0.58 | 0.60 | 0.76 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.18% | 31.54% | 65.89% | 91.33% |
| Free Cash Flow Growth | 18.02% | 3.04% | -40.28% | -62.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.47 | -0.16 | -0.03 | -0.00 |
| Interest Coverage | -60.19 | -73.75 | -32.34 | -87.07 |
| Efficiency | ||||
| Inventory Turnover | 1.97 | 1.72 | 2.59 | 4.74 |
| Cash Conversion Cycle | -54.49 | 70.45 | 229.65 | -215.25 |